Niacin in cardiovascular patients receiving statins

New England Journal of Medicine

Volumn 366, Issue 13, 2012, Pages 1255-1256

  Brouwers, Martijn C G J ^a   Stehouwer, Coen D A ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PLACEBO; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; LETTER; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84859072579     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1200980     Document Type: Letter

References (3)

1. The AIM-HIGH Investigators. Niacin inpatients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
2. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010;95:2727-35.
3. Brouwers MC, de Graaf J, van Greevenbroek MM, Schaper N, Stehouwer CD, Stalenhoef AF. Novel drugs infamilial combined hyperlipidemia: lessons from type 2 diabetes mellitus. Curr Opin Lipidol 2010;21:530-8.